ARID1A and cancer: This pattern aligns with the epigenetic immunomodulatory mechanisms reported by Ge et al. (2022) in gliomas, suggesting that ARID1A methylation drives pan-cancer immune evasion by reprogramming macrophage polarization and suppressing T-cell activation.